Valneva and pfizer report further positive phase 2 results, including booster response, for lyme disease vaccine candidate

Saint- herblain ( france) and new york (united states) , september 28 , 2021 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, and pfizer inc. (nyse: pfe), today announced further positive phase 2 results, including booster response, for lyme disease vaccine candidate vla15.
VALN Ratings Summary
VALN Quant Ranking